Pharmaceutical composite film formers intended for oral and injectable dosage forms are selected before formulation work begins against finished-product monographs, compendial test chapters, and ICH impurity guidelines. The following application scenarios are restricted to established downstream routes: immediate-release tablet coating, enteric multiparticulate coating, taste-masked granule deposition, non-gelatin capsule shell formation, extended-release film coating, oral thin film casting, and sterile in situ depot injection.

In side-vented coating pans with perforated drums and air-flow capacities above 1,200 m³/h, the aqueous film dispersion is sprayed onto preheated tablet cores through binary nozzles at an atomizing pressure of 1.0–1.8 bar and a peristaltic spray rate of 0.8–1.5 g/min/kg core load. The dispersion is prepared by hydrating the composite film former to 15–20% w/w solids in purified water under high-shear mixing at 3,000–5,000 rpm for 20–30 minutes, followed by passage through a 250 µm screen; triethyl citrate is added at 10–20% w/w of dry polymer and micronized talc at 30–40% w/w of dry polymer to suppress tack during coalescence. Addition to the tablet core is controlled at 2.0–3.5 wt% dry polymer relative to core mass, because below 2.0 wt% edge coverage on intagliated cores becomes discontinuous and above 3.5 wt% disintegration time can exceed 15 minutes for high-crush-strength cores. Inlet air temperature is maintained at 60–75 °C while exhaust air remains at 40–50 °C; core bed temperature is held at 40–45 °C to prevent over-wetting and logo bridging. The process is run with drum speed 2–8 rpm depending on pan diameter, and coating completion is confirmed by mass balance and scanning electron microscopy of film continuity. Compliance is anchored to USP <711> dissolution, USP <701> disintegration, Ph. Eur. 2.9.3 and 2.9.1, and residual solvents are controlled under ICH Q3C(R8); manufacturing records follow 21 CFR 210/211. Terminal product types are immediate-release film-coated tablets for analgesic, antihypertensive, and antidiabetic actives where cosmetic smoothing and light protection are required without altering drug release beyond the monograph limit.

What Process Window Governs pH-Triggered Enteric Film Formation on Multiparticulates?

Enteric protection with composite film formers is only obtained when the weight gain on tablet cores reaches 8–12 wt% and on pellets reaches 15–25 wt%, with the higher pellet range required because the increased surface-to-volume ratio lengthens acid diffusion pathways. The aqueous dispersion is prepared at 20% w/w solids and contains triethyl citrate at 15–25% w/w of dry polymer and talc at 30–50% w/w of dry polymer; polysorbate 80 at 0.1–0.3% w/w of the liquid dispersion is included to reduce foam during high-shear transfer. In Wurster bottom-spray equipment fitted with a 7–10 inch partition gap and a superficial air velocity of 1.2–1.8 m/s, the inlet temperature is set to 55–70 °C, while product temperature must remain at 28–32 °C; excursions above 32 °C produce premature film coalescence on the nozzle tip, and excursions below 28 °C cause agglomeration because evaporation is insufficient. Spray rate is held at 4–8 g/min/kg of pellet bed load, and post-coating curing is run at 40 °C for 2 hours to complete latex particle deformation. Acid-resistance testing follows USP <711> with an acid stage of 0.1 N HCl for 2 hours, where drug release must remain below 10%, followed by pH 6.8 phosphate buffer; batch release also requires USP <701> disintegration in simulated intestinal fluid and Ph. Eur. 2.9.3 dissolution. Residual solvents are controlled under ICH Q3C(R8). Terminal finished products from this route are gastro-resistant tablets, capsules filled with enteric-coated pellets, and sachet-delivered multiparticulates for proton-pump inhibitors or acid-labile enzymes.

When granule cores contain bitter APIs with aqueous solubility below 1 mg/mL, top-spray fluid-bed coating with a taste-masking composite film is used at a dry-polymer weight gain of 5–10 wt%; moisture-barrier protection for hygroscopic cores is achieved at 3–5 wt%, and both ranges should be verified by dissolution in simulated saliva rather than water alone. The coating dispersion is prepared at 10–15% w/w solids, with triethyl citrate at 8–15% w/w of dry polymer and micronized talc at 20–35% w/w of dry polymer; a water-soluble pore former is omitted to preserve delay in the oral cavity. In a top-spray fluid-bed granulator with an inlet air temperature of 55–70 °C, product temperature of 40–45 °C, and spray rate of 1.5–4.0 g/min/kg core load, the coating is applied to granules previously sieved to 200–800 µm; the production run is interrupted if outlet air humidity exceeds 60% because edge tack increases and the coating loses barrier continuity. Compliance is anchored to USP <1174> powder flow, USP <921> water determination, USP <786> particle size distribution, and Ph. Eur. 2.9.1 disintegration. Terminal product types include taste-masked granules for single-dose sachets, chewable tablets, and reconstitutable oral suspensions.

When Non-Gelatin Capsule Pins Are Dip-Coated with a Thermal-Gelling Composite

Non-gelatin hard capsule shells are produced by dip-coating stainless steel pins into a thermogelling aqueous solution of the composite film former at 18–22% w/v polymer solids, with a gelling agent added at 0.5–2.0% w/w of the wet solution and a plasticizer at 0.1–0.5% w/w of the wet solution to reduce brittleness after drying. The solution viscosity is maintained between 400–800 mPa·s at 25 °C; below this range the cast film drains unevenly from the pin, and above this range air bubbles entrained during mixing do not clear before dipping. Pins are preheated to 25–35 °C, immersed for 2–5 seconds, withdrawn with rotation to control thickness, and dried at 30–40 °C and 20–30% relative humidity for 30–60 minutes before trimming. Compliance for disintegration is tested by USP <701> and Ph. Eur. 2.9.1, and the shell polymer must meet the same residual solvent limits as oral dosage forms under ICH Q3C(R8); manufacturing controls follow 21 CFR 210/211. Terminal product types are hypromellose/vegetarian hard capsules intended for dry powder or pellet filling, with no gelatin-derived cross-linking risk.

Extended-release film coating performed in Wurster bottom-spray equipment requires a dry-polymer weight gain of 3–10 wt% on tablets and 10–30 wt% on pellets, but the functional range is narrower when the core contains hydrophilic swelling agents such as hypromellose or croscarmellose sodium. The aqueous dispersion is formulated at 18–20% w/w solids and includes dibutyl sebacate at 10–20% w/w of dry polymer, hypromellose as a pore former at 5–15% w/w of dry polymer, and talc at 20–40% w/w of dry polymer; the pore former content is the primary lever for adjusting release rate after the weight gain is fixed. During coating, inlet air is held at 55–65 °C, product temperature at 25–28 °C, and spray rate at 3–6 g/min/kg for pellets and 0.5–1.0 g/min/kg for tablets, with a post-coating annealing step at 60 °C for 2 hours to complete film coalescence. Release testing follows USP <724> drug release and USP <711> dissolution, with additional Ph. Eur. 2.9.3 testing where a European monograph applies; stability runs follow ICH Q1A(R2). Terminal product types are extended-release tablets and capsules filled with coated pellets for 12-hour or 24-hour release profiles. The operational boundary is that annealing above 60 °C must be avoided for cores containing low-melting waxes, and coating at product temperatures below 25 °C increases tackiness in high-humidity zones.

Oral Thin Film Casting Parameters and Mucosal Adhesion Limits

Oral thin films cast from the composite film former are formulated with polymer solids at 30–50 wt% of dry film, plasticizer at 5–15 wt%, API at 3–20 wt%, and a nonionic surfactant at 0.1–1.0 wt%; the wet mass is degassed under vacuum before casting to prevent entrapped air from creating pinhole defects. A slot-die or knife-over-roll coater applies the mass to siliconized polyester release liner at a gap of 400–800 µm, and drying is performed in a 60–80 °C multi-zone oven to residual moisture below 5% as determined by USP <921>. Dry film thickness is controlled at 50–120 µm, and the film is die-cut into 2–8 cm² units. Compliance for dissolution and dose uniformity follows USP <711> and USP <905>; mechanical integrity is characterized by ASTM D882-18 tensile testing, and biocompatibility for oral mucosal contact follows ISO 10993-1:2018 with cytotoxicity per ISO 10993-5:2009. Terminal product types are prescription and OTC oral thin films for antiemetic, antiallergic, and CNS actives. The operational boundary is that films with plasticizer levels above 20 wt% lose dimensional stability at 40 °C and should not be packed without cold-form foil or equivalent moisture protection.

Bioerodible Injectable Depot Formation Requires Strict Control of Solvent Exchange and Sterility

An injectable depot is prepared by dissolving the composite film former at 30–50 wt% in N-methyl-2-pyrrolidone or dimethyl sulfoxide and adding the active pharmaceutical ingredient at a drug-to-polymer ratio between 1:1 and 1:4 w/w; the final solution is filled by aseptic processing because terminal steam sterilization degrades the polymer and gamma irradiation above 25 kGy can reduce molecular weight by chain scission. Upon injection into an aqueous physiological environment, the solvent exchanges with water and the composite forms a bioerodible film depot at the intramuscular or subcutaneous site. Release kinetics are controlled by the polymer-to-drug ratio, solvent content, and depot surface area; when the polymer concentration falls below 30 wt%, the precipitated depot remains fragmented and releases drug too quickly, while concentrations above 50 wt% produce a syringeable viscosity above 2,000 mPa·s that complicates administration through 21-gauge needles. Sterility is verified by USP <71>, endotoxin by USP <85>, particulate matter by USP <788>, and parent product requirements follow USP <1>; biocompatibility testing follows ISO 10993-1:2018, ISO 10993-5:2009, and ISO 10993-11:2018. Residual solvent exposure is controlled under ICH Q3C(R8). Terminal finished product types are long-acting injectable depots for antipsychotic and hormone therapy, where release is intended for 1–3 months.